EGFR Alteration

CI-VAR-00000189Explore in graph →CIViC 4967

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Hepatocellular Carcinoma1
EGFR Amplification OR EGFR Alteration	Lenvatinib	Predictive	B	Supports Resistance	3	submitted	EID12052 The ctDNA of 46 patients with hepatocellular carcinoma was analyzed to investigate whether EGFR alterations could lead to lenvatinib resistance. Among these patients, 16 had been treated with lenvatin… (full text at CIViC) PMID 36708791 · Lim et al., 2023 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma1
EGFR Alteration	BMVC-8C3O + G-Quadruplex Stabilizer BMVC + OsimertinibCombination	Predictive	D	Supports Sensitivity Response	4	submitted	EID12139 NSCLC with EGFR activating alterations are frequently treated with the tyrosine kinase inhibitor, osimertinib. Though initially very effective, cancers cells often develop resistance to osimertinib th…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.